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Anthracyclines play an important role in treatment of variety types of cancer due to their high effectiveness and broad spectrum of ac-
tivity. However, a major limitation of their use is the dose-limiting cardiotoxicity. The inability to predict and prevent anthracycline 
cardiotoxicity is in part due to the fact that the molecular and cellular mechanisms remain controversial and incompletely understood. 
This review focuses on the biochemical basis of the anthracyclines toxic cardiac effects and pharmacological measures to their treat-
ment and preventing. We describe the theoretical substantiation of the enterosorption abilities for diminishing of cardiac damage.
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Anthracyclines (doxorubicin, daunorubicin, epi-
rubicin and others), taking into account their high 
effectiveness in the treatment of significant number 
of tumors, nowadays remain the most in-demand class 
of chemopreparations used in oncological practice, 
including pediatric oncology [3, 24, 118, 130]. 
By chemical structure these preparations are rep-
resented by hydrotetracenequinone chromophores 
containing three planar hexatomic rings which are 
linked with one or several sugar residues. �he dif-
ferences between separate preparations are related 
to the structure of aglycone or hydrocarbon part of the 
molecule (Fig. 1) [111]. 
Fig. 1. Chemical structures of main anthracyclines: doxorubicin 
(adriamycin) — DOX, daunorubicin — DNR, epirubicin — EPI, 
idarubicin — IDA. �he differences between drugs are marked 
by arrow
�he mechanisms of therapeutic action of anthracy-
clines are very multivarious [27, 67]: 1) DNA intercala-
tion and suppression of macromolecules synthesis; 
2) generation of free radicals with the following activa-
tion of lipid peroxidation (LPO); 3) binding with DNA 
molecule and its alkylation; 4) direct action toward 
membranes; 5) initiation of DNA damage by inhibition 
of topoisomerase II; 6) induction of apoptosis.
Anthracyclines possess expressed radiomimetic 
properties: the dynamics of disorders of blood system 
has a lot in common with the picture observed upon 
ionizing radiation injury [6, 26]. As well as other interca-
lating agents, anthracyclines are capable to suppress 
an activity of DNA reparation enzymes. It is known that 
the synthetic phase of cell mitosis and the transition 
point of presynthetic phase into synthetic one are the 
most sensitive to polychemotherapy. Anthracycline 
antibiotics implement their cytotoxic action simul-
taneously at different phases of mitotic cycle what 
determines their high therapeutic activity and in paral-
lel — significant side effects. 
One of the most available and effective prepara-
tions of this group, doxorubicin (DOX, adriamycin) 
is a derivative of rubomycin — 14-hydrorubomycin, 
and it is an irreplaceable component of Breast can-
cer treatment protocols, adjuvant and neoadjuvant 
chemotherapy of solid tumors in children, soft tissue 
sarcomas, aggressive lymphomas and hemoblastoses 
[67]. In the organism DOX is transformed into 13–di-
hydrodoxorubicinol (DOXol) by dint of cytochrome 
Р450 system and finally — into free radical state 
of semiquinone type. Free radicals of this anticancer 
antibiotic quickly react with molecular oxygen and 
promote an accumulation of LPO products and dam-
age of structural and functional organization of cells’ 
systems [27].
�he main side effects of anthracyclines are typical 
for the majority of antineoplastic preparations and are 
represented by nausea and vomiting, bone marrow 
depression, damaging of intestinal epithelium of and 
other mucosal surfaces as well as hair follicles, sup-
pression of reproductive function, etc. [125]. Differen-
tial peculiarity of DOX, as well as other anthracyclines, 
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is its significant cardiotoxic action along with other 
side effects characteristic for the majority of cyto-
static agents. Dose dependent injury of cardiac muscle 
is considered the most significant factor that limits the 
use of the preparations related to this type [34, 37].
Acute and especially chronic DOX cardiotoxicity 
leads finally to fatal dilated cardiomyopathy (DCMP), 
and results in so dangerous clinical manifestations 
(in the case of development of congestive heart 
failure (CHF) the mortality rate reaches 60% [132]), 
that modern schemes of monitoring of side effects 
of anthracycline chemotherapy prescribe an evaluation 
of left ventricular ejection fraction before treatment 
initiation and after achievement of ½ of cumulative 
dose with the following measuring of this index after 
each new treatment course with the use of anthracy-
clines and continuation of such control on 3rd, 6th and 
12th months after therapy termination [21]. According 
to other data, 50% of patients which had experience 
of anthracycline chemotherapy die from CHF caused 
by their cardiotoxicity during two years from the mo-
ment of diagnosis of anthracycline cardiomyopathy 
despite the performed therapy [41, 113].
�here are the following risk factors of cardiac le-
sion development: 1) cumulative dose of the prepara-
tion > 550 mg/m2 and higher (after an achievement 
of cumulative dose, as a rule DCMP develops during 
a year); 2) age (under 3 and after 65 years); 3) radio-
therapy of mediastinum; 4) simultaneous administra-
tion of other cardiotoxic agents; 5) female gender; 
6) concomitant cardiac pathology; 7) bolus admin-
istration of the preparation [35]. �he cases of CHF 
development have been reported also for obtained 
cumulative dose that was twice lower than the critical 
one [62, 114].
�he mechanisms of damage of the heart upon 
anthracycline cardiomyopathy are multiple and are 
not completely studied yet. It is supposed that car-
diotoxicity is related to generation of free radicals by 
“anthracycline-iron” complex and injury of myocar-
dium caused by LPO products [45, 67]. EPR-studies 
have shown that during this process mitochondrial, 
nuclear and microsomal reductases catalyze an at-
tachment of electron to quinone residue of tetracycline 
ring of anthracyclines leading to formation of semi-
quinone free radical that generates superoxide anion 
radical О2•– and hydrogen peroxide H2O2. �oxicity 
of the latest multiply increases upon reaction with low 
molecular weight iron (LMW Fe). In this case, ferritin 
is a physiologic protector that serves as a safe stor-
age of cytosol source of high molecular weight iron 
compounds in soluble and nontoxic form. However, 
LMW Fe could be replaced from this transport form 
by О2•– radical and anthracycline semiquinone radi-
cals [131]. In the majority of cells defense enzymes 
of antioxidant system (superoxide dismutase, cata-
lase and glutathione peroxidase) reduce to minimum 
the damaging action of these factors, but the pool 
of endogenous antioxidants of cardiomyocytes 
is very limited and couldn’t provide adequate reaction 
to anthracycline-induced oxidative stress what finally 
leads to degeneration and descent of cardiac muscle 
contractility (Fig. 2).
Fig. 2. �he “iron and free radical hypothesis of cardiotoxicity 
of anthracyclines (DOX)”. F/FH2 — oxidized/reduced flavopro-
teins (e.g., NADH dehydrogenase, NADPH cytochrome P450 re-
ductase); LMW Fe(II), low molecular weight Fe(II); •OH, hydroxyl 
radical; FeIV=O, ferryl ion; DOX•Fe, doxorubicin-iron complex
By an opinion of some authors, as an alternative 
to a theory of free radical injury of cardiomyocytes, 
or as its supplement, so called “metabolic” theory 
could be considered [37, 62, 67]. DOX cardiotoxicity 
could be explained by cardiac muscle accumulation 
of its highly reactive alcoholic metabolite doxorubicinol 
(DOXol) that inhibits Са2+, Mg2+-dependent A�Pase 
of sarcoplasmic reticulum, f0-f1 proton pomp of mi-
tochondria and transport of Na+-Ca2+ in sarcolemma, 
thus disturbing intracellular energetic metabolism, ion 
gradients and balance of Ca2+ [62, 66]. It is known that 
mitochondria, the main suppliers of A�P to cells, yield 
up to 30% of total myocardium weight. An important 
factor that promotes toxic action of DOX on cardiomyo-
cytes, is its high affinity to cardiolipin — anionic phos-
pholipid which is specific for mitochondrial membrane 
and important component supporting of mitochondrial 
structure and function as well as total energetic me-
tabolism and survival of cells [28, 42, 73]. Another 
factor of cardiotoxicity caused by DOX is the violation 
of mitochondrial membrane permeability [70]. 
In a number of studies there has been found a tight 
relation and certain prognostic value of elevated 
level of proinflammatory cytokines, especially tumor 
necrosis factor-α (�NF-α), Interleukin-1β (IL–1β), 
Interleukin-6 (IL-6), and their soluble receptors with 
the intensity of heart failure (HF) and decreasing of left 
ventricular ejection fraction. Elevated cytokines’ level 
in case of HF is not only a marker of immune activation, 
i.e. epiphenomenon of severe course of disease, but 
also it directly affects the development of myocardial 
dysfunction and remodeling of left ventricle [65, 126]. 
�he mostly studied effects of �NF–α are negative ino-
tropic action, myocardial remodeling, and myocardial 
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fibrosis, reinduction of fetal phenotype of myocardium, 
apoptosis of cardiomyocytes, endothelial dysfunction, 
skeletal muscle myopathy, myocardium cachexia [56]. 
Increased levels of Interleukin-8 promote the deve-
lopment of insulin resistance and diabetes mellitus 
in patients with DCMP [8]. 
In last time there is actively discussed the theory 
of cardiomyopathy development as a consequence 
of endotoxicosis (Fig. 3). Colon that serves as the 
main depot of bacterial endotoxins (LPS) is sensitive 
to damaging action of antiblastoma preparations. In-
jury of colon mucosa, edema and ischemia of enteric 
wall promote bacterial translocation leading to release 
of LPS, immuno-inflammatory activation and cytokines 
release [47, 107].
HF
(decreased left ventri-
cular function plus
endothelial dysfunction)
Intestinal
hypoperfusion
Intestinal mucosal
ischemia
Increased intestinal
permeabilityCytokine production
Activation of mono-
cytes/macrophages
in blood and liver
Endotoxemia
Translocation
of bacteria
and/or endotoxin
Fig. 3. �he role of the gut in HF [Krack A et al., 2005]
It’s important to note that approximately 30% of DOX 
is eliminated with bile in unaltered form thus causing 
additional cytotoxic action toward intestinal mucosa [2].
As other genotoxic drugs, DOX initiates р53–medi-
ated cell death [117]. It is known that p53 gene is an im-
portant regulator of cell division and death. It has been 
demonstrated that its chemical inhibition prevents 
DOX-induced cell death and the loss of mitochondrial 
membrane potential [52]. �here have been described 
also alterations of vasoactive mediator production upon 
HF development, in particular, of endothelin-1 and nitric 
oxide [15, 23, 104]. Vasoconstrictive cytokines, endo-
thelin-1 and big endothelin-1, which are responsible for 
contractility, arrhythmogenesis and remodeling of myo-
cardium, are related also to the category of prognostic 
indicators of patient’s survival ill with HF [43, 61, 95] and 
play an important role in pathogenesis and progression 
of cardiomyopathy. 
Certain role in CHF development is thought 
to be related to oxidant-dependent activation of heat 
shock factors by DOX with the following expression 
of heat shock proteins (Hsp): Hsp25 which leads 
to actin destruction [123], and Hsp60, which functions 
mainly in mitochondria [44]. Also, there have been 
described such processes as enzymatic activation 
of binding of DOX with nuclear DNA [112], selective 
alteration of cardiac mRNA coding important pro-
tein of myocardium as αС–actin [91], and elevation 
of phospholipase activity mediated by LPO [83]. Some 
investigators attach great importance to dysfunction 
of calcium channels [116], proteolysis of titin (known 
also as connectin which plays an important role 
in muscle contractility), and disintegration of cardiac 
transcription factors concordance [19, 33].
Subclinical myocardial damage caused by anthra-
cyclines could be diagnosed with the use of standard 
ECG, Holter monitoring, high resolution ECG, evalu-
ation of heart rhythm variability, echocardiography, 
radionuclide ventriculography, myocardium scintigra-
phy, magnetic resonance tomography, analysis of con-
centrations of cardiac enzymes and other biochemical 
markers of cardiomyocyte damage [128]. However, 
upon subclinical heart damage, the majority of routine 
monitoring methods demonstrates low prognostic sen-
sitivity while myocardial biopsy is an invasive process, 
technically complex and unsafe [4, 89]. �hat’s why the 
use of biochemical markers for monitoring of anthracy-
cline based chemotherapy and selection of prophylaxis 
of cardiomyopathy development in patients without 
notable manifestations of myocardial damage seems 
to be more reasonable. Presently, the use of lactate de-
hydrogenase (LDG) and creatinphosphokinase (CPK) 
is not recommended because of their low specificity. 
In this sense, natriuretic peptides (atrial natriuretic 
peptide — ANP and brain natriuretic peptide — BNP) 
are more informative. �hese neurohormones play a key 
role in the support of compensated state in patients 
with initial CHF manifestations, firstly, due to their 
influence on renal homeostasis, water-electrolytic 
balance and renin-angiotensin-aldosterone system 
at the conditions of decreased cardiac ejection. 
�erminal fragment of BNP precursor — N�-proBNP 
(N-terminal prohormone of brain natruretic pep-
tide) — has more prolonged half-life period, so the 
latest studies have been done with N�-proBNP which 
is secreted in heart ventricles in response to volume 
and pressure overloads [21]. Blood plasma content 
of N�-proBNP and BNP are increased during the first 
year after chemotherapy with moderate anthracycline 
doses [16]. It is necessary to note that there have been 
obtained no valuable proofs of prognostic significance 
of natriuretic peptide levels, but an increase of their 
blood plasma concentration could be used for selec-
tion of patients with higher risk of heart dysfunction 
development in late-term and respectively these who 
require more intense supportive therapy. �here has 
been also detected a relation between concentration 
of carnitine, lipid peroxidase level in blood plasma and 
myocardial dysfunction [11, 50]. 
Despite a large number of proposed biochemical 
markers, the most reliable method of myocardial dys-
function prognosis is considered to be determination 
of level of cardiac troponin � (c�n�) which is excreted 
in blood due to cardiomyocyte membrane destruction 
[82]. In many studies it has been shown that even moder-
ate elevation of c�n� induced by DOX, is associated with 
histological signs of myocardial damage [36]. 
By clinical patterns one could distinguish acute and 
chronic cardiotoxicity [37, 50, 129]. Acute form deve-
lops at the moment of administration of the preparation 
or few hours after it and is manifested by transitory ar-
rhythmia and hypotension that could be treated effec-
tively. Chronic cardiotoxicity leads to the development 
of congestive HF that is refractory to standard inotropic 
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agents [66]. Some authors distinguish its early form 
(which occurs during the first year) and late form (that 
develops from 1st till 30th years with the pike at 7–10th 
years) [62]. Creutzig U. et al. [17] point out that more 
often chronic cardiomyotoxicity develops in children 
who already underwent an acute form of cardiomyo-
toxicity or received repeated treatment courses with 
anthracyclines, even in the cases when the preparations 
with lower cardiotoxic potential have been used. 
�aking into account the facts that in people with 
survival higher than 5 years after anticancer treat-
ment with the use of anthracyclines, the mortality risk 
related to heart pathology is 10 fold higher than that 
in total population [99], as well as nearly 60% of pa-
tients who survived after childhood cancer, receive the 
preparations exactly from this group [102], the search 
for effective methods of prophylaxis and mitigation 
of cardiotoxic effects of anthracyclines is extremely 
actual. First of all, it is the screening for risk factor 
presence in the patients, correction of cumulative dose 
of anthracyclines, and active monitoring of subclinical 
myocardial damage [4]. �he synthesis and deve-
lopment of new preparations with lower cardiotoxic 
action including their liposomal forms, is important, 
too [13, 38, 97, 105, 119]. Also, it is reasonable to use 
active curative-prophylactic administration of cardio-
protectors with antioxidant properties, in particular, 
organic amifostine thiosulphate [94], L-carnitine 
[133], N-acetylcysteine, vitamin Е [40], thiotriazoline 
[14], flavonoid rutoside [121], etc. �here are also 
used cholesterol-depletion agent probucol [49, 58], 
beta-blockers [63], calcium channel inhibitors [69, 
122] and their combination with activators of A�P-
sensitive potassium channels [68]. Rovustatin and 
probucol possess fine antiapoptotic potential toward 
cardiomyocytes and are classic lipid-lowering drugs 
[84, 106]. �here is also known a cardioprotective 
effect of adenosine that increases intracellular A�P 
concentration and adenylate potential in total [72]. 
By the data of Cardinale D. et al., early administration 
of ACE-blocker enalapril nearly totally prevents the 
development of HF in the risk group [12]. However, 
in analogous study devoted to cardioprotective ac-
tion of enalapril in children who underwent intense 
chemotherapy, the use of this preparation resulted 
just in moderate effect [110]. Interesting experimental 
results have been recorded upon the use of erythro-
poietin, thromboplastin, and synthetic prostacyclin 
iloprost usually used for treatment of pulmonary ar-
terial hypertension, as cardioprotectors [53, 55, 71]. 
By our opinion, the use of granulocyte colony stimu-
lating factor for prophylaxis of DOX-induced DCMP 
seems to be especially perspective [54], because 
this cytokine is simultaneously the most potent my-
eloprotective agent. Iron-chelating agent cardioxane 
demonstrates good results in prophylaxis of acute and 
chronic DOX-induced cardiomyopathy; however, its 
influence on efficacy of cytostatic anthracycline-based 
therapy is speculative [29, 32, 57]. Cardioxane usage 
is limited by its characteristic myelotoxicity, nausea 
and diarrhea [25]. 
So, despite intense scientific efforts, the mecha-
nisms of cardiotoxicity development upon anthra-
cycline-based chemotherapy remain incompletely 
studied yet while the possibilities of modern preventive 
and curative strategies, unfortunately, are still limited. 
An absence of safe methods of prophylaxis and treat-
ment of anthracycline cardiomyopathy forces the 
search of new ways to solve this problem. From this 
point of view, the use of modern approaches of sorp-
tion therapy is very perspective. It is known that sorp-
tion technologies are among the main components 
of efferent medicine — science about curative mea-
sures directed toward removal of toxic compounds 
of endogenous and exogenous origin from body fluids 
[74]. �he most widely used types of sorption detoxi-
fication are purification of blood and its components 
by hemosorption, oral administration of large doses 
of sorption materials, and also application sorption 
therapy of burns and wounds. It s commonly known 
that in cancer patients an expressed endogenous 
intoxication is determined by tumorogenous process 
as well as by curative means directed toward destruc-
tion of malignant lesions [76]. So called “tumor dis-
position” (the state developed during natural course 
of malignant pathology) is based on the stable LPO 
activation, development of oxidative stress [59], and 
“metabolic intoxication” which is related to dysfunction 
of excretory organs, i.e. accumulation of excessive 
amounts of toxic intermediate and terminal metabo-
lites [100]. �hus, the necessity of use of detoxifica-
tion means and methods in oncology is evident. For 
example, upon DMCP there have been received 
positive results of plasmaimmunosorption that were 
expressed in decreased level of а N�-pro BNP marker 
and significant elevation of ejection fraction from 
25.5 to 30.9% [20]. Very perspective and effective 
in such cases could be another method of detoxifica-
tion — enterosorption that is noninvasive in contrary 
to hemosorption, and plasmapheresis.
�he term “enterosorption” has been used since 
1982 [77]. 
Local mechanisms of curative action of enterosorbents [Niko-
laev V.G., 2009]:
1) adsorption of exogenic toxic compounds; 
2) adsorption of toxins that diffuse in intestinal lumen from blood;
3) binding of toxic compounds excreted together with digestive juices;
4) adsorption of toxic metabolites generated in GIT (indol, skatol etc.); 
5) sorption modification of diet via selective adsorption of its compounds; 
6) fixation and transfer of physiologically active compounds (enzymes, bile 
acids etc); 
7) enhancement of indigestible residue volume by the type of action of di-
etary fibers;
8) catalytic action;
9) coating and cytoprotective action; 
10) structuring of intestinal content;
11) formation of aggregates and flocculates containing microbes and vi-
ruses;
12) direct bactericidal action;
13) complex formation and chelating
14) modification of chemical composition of intestinal content hindering 
pathogenic flora propagation;
15) normalization of enteric microbiocenosis;
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16) elimination of meteorism, improvement of blood supply of intestine, 
stimulation of peristalsis.
Systemic (extraintestinal) effects of entersorption 
are: 1) prevention or attenuation of toxico-allergic reac-
tions; 2) prophylaxis of somatogenic stage of exotoxi-
cosis; 3) decreasing of metabolic load on excretory and 
detoxification organs; 4) positive correction of a number 
of metabolic processes and elements of immune sta-
tus; 5) improving of humoral homeostasis, elimination 
of imbalance of biologically active compounds; 6) res-
toration of integrity and penetrability of cell membranes 
as well as regenerative potential of organs and tissues; 
7) suppression of LPO processes; 8) improvement 
of lipidogram indexes; 9) normalization of cytokine 
profile of blood plasma [5, 78]. 
Multifaceted action of enteral sorption detoxifica-
tion has made it an important component for treatment 
of such pathologies as acute intestinal infections [81], 
colitis and enterocolitis, dysbacteriosis [108], various 
intoxications [90], kidney diseases [22], especially 
which are accompanied by chronic renal insufficiency 
[75], and also atherosclerosis, diabetes mellitus, 
bronchial asthma, viral hepatitis, some autoimmune 
and skin diseases [109]. 
Influence of enterosorption on the development 
of oxidative stress has exceptional importance. 
It is known that increasing of usual speed of free radical 
oxidation serves as universal mechanism of develop-
ment of many pathologic processes [51]. In experimen-
tal studies there has been shown an efficacy of silicon-
organic enterosorbent Enterosgel for decreasing the 
content of LPO products and improvement of antioxi-
dant defense at the background of usage of combined 
antituberculosis drugs [86, 93]. Also there has been de-
scribed an effectiveness of chitosan for correction of ex-
cessive LPO upon the use of rifampicin and isoniazid 
[103]. Introduction of Polysorb into treatment schemes 
for patients with tuberculosis increases an efficacy 
of polychemotherapy and decreases the manifestation 
of side effects [39]. Administration of SUMS-1 en-
terosorbent decreases the LPO level, affects the shape 
of pharmacokinetic curves for isoniazid without altera-
tion of total area under the curve, and attenuates drug 
resistance to some groups of antibiotics [46]. It was 
found the decreasing of negative influence of excessive 
LPO by enterosorbents improves prognosis upon toxic 
and viral hepatitis [98, 124]. �here has been registered 
a positive effect of enterosorption in case of conges-
tive HF developing due to ischemic heart disease and 
arterial hypertension. Schemes which included carbon 
sorbent SCN and cardiac glycosides were by 21% 
(Р<0.05) more effective than the use of strophantin 
or digoxin without SCN [80]. Enterosgel successfully 
protects the membranes and stabilizes hepatocyte ly-
sosomes during aggressive anticancer chemotherapy 
[30]. In mentioned study cyclophosphamide, vincristin, 
and prednisolone were administered to rats. In groups 
with concomitant Enterosgel usage (1 g/kg for 7 days 
after cytostatics administration), there has been ob-
served the decreasing of cytolysis markers (AL�, AS�) 
and lysosomal enzymes. So, as it has been mentioned 
above, enterosorbents reveal expressed distant effects 
without systemic pharmacokinetics and significantly 
decrease toxic loads on excretory body systems [90, 
127], as well as endogenous intoxication level upon 
severe infectious diseases [1] and burns [87, 120].
Cytokines are universal regulators of homeostasis, 
which may initiate multiple pathologic processes [60]. 
�he decreasing of the level of proinflammatory cyto-
kines upon the influence of enterosorbents observed 
in the case of thermal trauma [88], food allergy [64, 
85], intestinal infection and measles [115], pancreone-
crosis [96], creates abilities for effective use of en-
terosorbents in a number of other clinical situations 
including anticancer chemotherapy. 
�here have been described positive clinical effects 
of carbon sorbent SUMS-1 in cancer treatment what 
allowed to decrease the dosages of analgesics, myelo-
toxicity of polychemotherapy, and level of endogenous 
intoxication [10]. Granulated carbon enterosorbent 
SCN have demonstrated the decreasing of rubomycin 
myelotoxicity in rats with inoculated tumors as well 
as the presence of moderate leukostimulative effect 
upon clinical polychemotherapy [9]. Also it has been 
shown that carbon enterosorbent Carboline possess 
notable antiemetic activity upon different polychemo-
therapy schemes [92]. In patients with resectable colon 
cancer an introduction of enterosorption into the com-
plex of curative actions has decreased the frequency 
of side effects development from 7.4 to 2.9%, and 
increased total 5-years survival from 66.1 to 79.3% [18]. 
Adsorption of endogenous toxins generated 
in intestines has a special value in the cases when 
barrier function of intestinal epithelium is attenuated, 
in particular upon cytostatic therapy. In such situation 
the presence of potent adsorbents in intestinal lumen 
prevents translocation of increased amounts of natu-
ral products of enteric metabolism (indols, phenols, 
scatol etc.), bacterial toxins, and intestinal microflora 
into bloodstream [5, 74]. Beneficial effects of entero-
sorption in acute intestinal infections is determined 
by a complex of factors: adsorption of bacterial toxins 
and inflammatory mediators, elimination of secretory di-
arrhea, total change of chemical composition of enteric 
content, suppression of pathogenic microflora growth 
[74, 81]. Also Enterosgel is capable to adsorb enteric 
bacteria on its surface and destruct some of them [79]. 
Enterosorbents decrease adhesion of microorganisms 
of the surface of intestinal mucosa and bacterial trans-
location [48]. Enterosorbent-bound microorganisms, 
toxins and metabolic products are removed from a body 
and therefore, enterosorption decreases LPS level [31, 
101]. Prolonged administration of SUMS-1 enterosor-
bent promoted an increase in the number and height 
of microvillus in small bowel, activation of mitochondrial 
apparatus of enterocytes, and possibly total elevation 
of their adaptive potential [7]. So, enterosorption which 
is widely used in treatment of pathologies of gastro-
intestinal tract and affects their various pathogenic 
moments, seems to be very perspective for treatment 
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of gastroenteropathy which develops due to cytosta-
tics application, and also for binding of anthracyclines 
excreted with the bile, because enterohepatic recircula-
tion of the latest enhances their cytotoxic effect toward 
intestines and liver.
�aking into account the abovementioned role 
of LPO activation, proinflammatory cytokines, bacte-
rial endotoxins in the development of cardiotoxic ef-
fects of anthracyclines, and in particular, DOX, as well 
as positive effects of enterosorbents in oncological 
clinics and experimental oncology, one could consider 
reasonable to include enterosorption into the schemes 
of anticancer therapy with the use anthracycline anti-
biotics for decrease of their system toxicity, first of all, 
cardiotoxicity. 
Hemocarboperfusion which exhibits evident pa-
rallels between mechanisms of its action and mecha-
nisms of development of anthracycline cardiotoxicity, 
also looks to be prospective method of the treatment 
of immediate and late cardiac complications of anthra-
cycline chemotherapy.
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